Status:
COMPLETED
Safety and Efficacy of Ranibizumab in Diabetic Macular Edema With Center Involvement
Lead Sponsor:
Novartis
Conditions:
Diabetic Macular Edema
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study evaluated the safety and efficacy of ranibizumab on retinal edema and visual acuity in patients with diabetic macular edema with center involvement.
Eligibility Criteria
Inclusion
- Diabetic macular edema with center involvement in at least one eye
- Type 1 or type 2 diabetes mellitus diagnosed 2 years prior to screening
- Laser photocoagulation in the study eye can be withheld for at least 3 months after randomization
Exclusion
- Patients with uncontrolled systemic or ocular diseases
- Have any history of any intraocular surgery in the study eye within the past 6 months preceding screening
- Conditions that require chronic concomitant therapy with systemic or topical ocular corticosteroids
- Other protocol-defined inclusion/exclusion criteria applied to the study.
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
151 Patients enrolled
Trial Details
Trial ID
NCT00284050
Start Date
October 1 2005
End Date
June 1 2008
Last Update
February 24 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis
Basel, Switzerland